Neuromyelitis Optica Spectrum Disorders: Still Evolving and Broadening

Overview

Journal Curr Opin Neurol

Specialty Neurology

Date 2019 Mar 21

PMID 30893099

Citations 62

Authors

Kazuo Fujihara

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The diagnostic criteria of neuromyelitis optica spectrum disorders (NMOSD) has been revised in the past 20 years and pathological and therapeutic data have been accumulated. This review provides an overview of evolution and broadening of the concept of NMOSD.

Recent Findings: NMOSD encompassing brain syndrome as well as optic neuritis and acute myelitis is now classified into aquaporine-4 (AQP)-antibody-seropositive and aquaporine-4 (AQP)-antibody-seronegative diseases, detecting more patients earlier than before. Seronegative NMOSD includes cases of myelin oligodendrocyte glycoprotein (MOG)-antibody-seropositive disease with its unique clinical spectrum somewhat different from AQP4-antibody-seropositive NMOSD. Pathologically, NMOSD includes AQP4-antibody-seropositive autoimmune astrocytopathic disease and MOG-antibody-seropositive inflammatory demyelinating disease. Double seronegative group needs further research. Therapeutic options of NMOSD has taken shape and first-ever clinical trials of monoclonal antibodies have been done. In retrospect, relapsing NMO in the studies preceding the discovery of AQP4-antibody had features of AQP4-antibody-seropositive NMO whereas monophasic NMO was similar to AQP4-antibody-seronegative/MOG-antibody-seropositive NMO.

Summary: The clinical, pathological and therapeutic concepts of NMOSD have evolved and broadened over the last two decades following the detection of AQP4 antibodies and MOG antibodies in the patients. Double seronegative NMOSD is a current research focus, but now we may need to reconsider how NMOSD should be defined.

Citing Articles

Serum Low-Density Lipoprotein Cholesterol Levels are Associated with Relapse in Neuromyelitis Optica Spectrum Disorder.

Ding J, Chen F, Song Y, Li H, Ai X, Chen Y J Inflamm Res. 2024; 17:8227-8240.

PMID: 39525310 PMC: 11549894. DOI: 10.2147/JIR.S489723.

Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder.

Li Y, Sun J, Zhuo Z, Guo M, Duan Y, Xu X AJNR Am J Neuroradiol. 2024; 45(12):1901-1909.

PMID: 39510804 PMC: 11630882. DOI: 10.3174/ajnr.A8480.

Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan.

Takahashi Y, Kezuka T, Shikishima K, Yamagami A, Chuman H, Nakamura M Jpn J Ophthalmol. 2024; 69(1):81-92.

PMID: 39470886 PMC: 11821680. DOI: 10.1007/s10384-024-01129-4.

Biomarkers for neuromyelitis optica: a visual analysis of emerging research trends.

Li X, Zhang J, Zhang S, Shi S, Lu Y, Leng Y Neural Regen Res. 2024; 19(12):2735-2749.

PMID: 38595291 PMC: 11168523. DOI: 10.4103/NRR.NRR-D-24-00109.

Advances in the long-term treatment of neuromyelitis optica spectrum disorder.

Anderson M, Levy M J Cent Nerv Syst Dis. 2024; 16:11795735241231094.

PMID: 38312734 PMC: 10836138. DOI: 10.1177/11795735241231094.

References

Hamid S, Elsone L, Mutch K, Solomon T, Jacob A . The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Mult Scler. 2016; 23(2):228-233. DOI: 10.1177/1352458516663853. View

Waters P, Woodhall M, OConnor K, Reindl M, Lang B, Sato D . MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015; 2(3):e89. PMC: 4370386. DOI: 10.1212/NXI.0000000000000089. View

Roemer S, Parisi J, Lennon V, Benarroch E, Lassmann H, Bruck W . Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130(Pt 5):1194-205. DOI: 10.1093/brain/awl371. View

Jurynczyk M, Jacob A, Fujihara K, Palace J . Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol. 2018; 19(3):187-195. DOI: 10.1136/practneurol-2017-001787. View

Kitley J, Waters P, Woodhall M, Leite M, Murchison A, George J . Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014; 71(3):276-83. DOI: 10.1001/jamaneurol.2013.5857. View

Wingerchuk D, Lennon V, Pittock S, Lucchinetti C, Weinshenker B . Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66(10):1485-9. DOI: 10.1212/01.wnl.0000216139.44259.74. View

Ciccarelli O, Thomas D, De Vita E, Wheeler-Kingshott C, Kachramanoglou C, Kapoor R . Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. Ann Neurol. 2013; 74(2):301-5. DOI: 10.1002/ana.23909. View

Hyun J, Jeong I, Joung A, Kim S, Kim H . Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology. 2016; 86(19):1772-9. DOI: 10.1212/WNL.0000000000002655. View

Lennon V, Kryzer T, Pittock S, Verkman A, Hinson S . IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202(4):473-7. PMC: 2212860. DOI: 10.1084/jem.20050304. View

10.

Jarius S, Paul F, Aktas O, Asgari N, Dale R, De Seze J . MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018; 15(1):134. PMC: 5932838. DOI: 10.1186/s12974-018-1144-2. View

11.

Misu T, Fujihara K, Nakamura M, Murakami K, Endo M, Konno H . Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med. 2006; 209(3):269-75. DOI: 10.1620/tjem.209.269. View

12.

Jiao Y, Fryer J, Lennon V, Jenkins S, Quek A, Smith C . Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013; 81(14):1197-204. PMC: 3795610. DOI: 10.1212/WNL.0b013e3182a6cb5c. View

13.

Jarius S, Wildemann B . Devic's disease before Devic: On the contribution of Friedrich Albin Schanz (1863-1923). J Neurol Sci. 2017; 379:99-102. DOI: 10.1016/j.jns.2017.05.044. View

14.

Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y . Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010; 75(3):208-16. DOI: 10.1212/WNL.0b013e3181e2414b. View

15.

OConnor K, McLaughlin K, De Jager P, Chitnis T, Bettelli E, Xu C . Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007; 13(2):211-7. PMC: 3429369. DOI: 10.1038/nm1488. View

16.

Jurynczyk M, Messina S, Woodhall M, Raza N, Everett R, Roca-Fernandez A . Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017; 140(12):3128-3138. DOI: 10.1093/brain/awx276. View

17.

Waters P, McKeon A, Leite M, Rajasekharan S, Lennon V, Villalobos A . Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78(9):665-71. PMC: 3286228. DOI: 10.1212/WNL.0b013e318248dec1. View

18.

Hamid S, Whittam D, Mutch K, Linaker S, Solomon T, Das K . What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017; 264(10):2088-2094. PMC: 5617862. DOI: 10.1007/s00415-017-8596-7. View

19.

Wingerchuk D, Hogancamp W, OBrien P, Weinshenker B . The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53(5):1107-14. DOI: 10.1212/wnl.53.5.1107. View

20.

Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y . Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009; 80(5):575-7. DOI: 10.1136/jnnp.2008.150698. View